Related Experiment Video
Updated: Jun 24, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Guanidinoacetate methyltransferase deficiency (GAMT)
1Huntlywood, Wilmslow, UK. neil-gordon@doctors.org.uk
Brain & Development
|March 18, 2009
Summary
Guanidinoacetate N-methyltransferase (GAMT) deficiency is a treatable metabolic disorder. Early diagnosis and creatine supplementation can improve symptoms like seizures and movement disorders, especially in patients with developmental delays.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Guanidinoacetate N-methyltransferase (GAMT) deficiency is an inherited metabolic disorder.
- It is characterized by a range of neurological and developmental symptoms.
- Increasingly, metabolic disorders are becoming treatable, including GAMT deficiency.
Purpose of the Study:
- To review the symptoms, diagnosis, and treatment of GAMT deficiency.
- To highlight the importance of considering GAMT deficiency in patients with unexplained learning disorders.
Main Methods:
- Review of clinical symptoms and genetic inheritance patterns.
- Discussion of diagnostic methods including MRI and biochemical analysis (urine guanidinoacetate, plasma creatine).
- Description of treatment strategies involving creatine supplementation and dietary modifications.
Main Results:
- GAMT deficiency presents with delayed language, learning disorders, autistic behavior, seizures, and movement disorders.
- Diagnosis is supported by MRI findings and confirmed by elevated urine guanidinoacetate and low plasma creatine.
- Treatment with creatine and dietary changes improves seizures and movement disorders.
Conclusions:
- GAMT deficiency is a treatable metabolic disorder with significant neurological impact.
- Early diagnosis and intervention are crucial for managing symptoms.
- Consideration of GAMT deficiency is warranted for unexplained developmental and neurological issues.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:48ATP Synthase: Mechanism
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased ATP...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...